{"nctId":"NCT01388985","briefTitle":"Simplifying the Rabies Pre-exposure Vaccination","startDateStruct":{"date":"2011-10"},"conditions":["Rabies"],"count":500,"armGroups":[{"label":"Standard vaccination schedule","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Human Diploid Cell Vaccine (HDCV) rabies vaccine"]},{"label":"Accelerated vaccination schedule","type":"EXPERIMENTAL","interventionNames":["Biological: Human Diploid Cell Vaccine (HDCV) rabies vaccine"]}],"interventions":[{"name":"Human Diploid Cell Vaccine (HDCV) rabies vaccine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Willingness to provide written consent\n* Seronegative for rabies\n* Belgian soldiers who are deployable and visit the Travel clinic in Brussels during their preparation phase before deployment OR military students at the schools of Belgian Defense are eligible in preparation of an overseas exercise or during the scheduled vaccination program at the end of their studies\n* Prepared to follow the study schedule\n\nExclusion Criteria:\n\n* Subjects who have had rabies vaccination (complete or incomplete) in the past due to post-exposure prophylaxis.\n* Subjects with a known allergy to one of the components of the vaccine.\n* Immune depressed persons or intake of immunodepressant medication.\n* Subjects who take mefloquine\n* Planned deployment to overseas areas within 35 days.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"47 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With a Boostability of the Rabies Antibodies After Booster Vaccination","description":"The primary endpoint is the number of particpants with a boostability of the rabies antibodies on day 7 after booster vaccination, carried out at years 1 to 3 after initial vaccination. A rabies serology value of more than 0,5 IU/ml (international unit/milliliter) on day 7 after booster vaccination is considered to be protective. Subjects showing this serology value at day 7 are considered to be boostable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"185","spread":null},{"groupId":"OG001","value":"183","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Rabies Serology More Than 0.5IU/ml After Primary Vaccination","description":"Number of participants that have a Rabies serology more than 0,5 IU/ml on day 35 after primary vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"231","spread":null},{"groupId":"OG001","value":"238","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Particpants With a Rabies Serology More Than 10IU/ml After Primary and Booster Vaccination","description":"Number of participants that have a Rabies serology more than 10 IU/ml on day 35 after primary vaccination, and after booster vaccination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"167","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Particpants Experiencing Adverse Events","description":"Number of participants experiencing Adverse events within one week after initial and booster vaccinations","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":null},{"groupId":"OG001","value":"190","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing Serious Adverse Events","description":"Number of participants experiencing a Serious adverse event within 28 days after initial and booster vaccinations","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":249},"commonTop":[]}}}